Synagis labeling adds anaphylaxis warning
Executive Summary
MedImmune revises Synagis (palivizumab) labeling to include incidences of anaphylaxis in the warnings section. "Very rare cases of anaphylaxis (<1 case per 100,000 patients) have been reported following re-exposure to Synagis," revised labeling for the respiratory syncytial virus humanized monoclonal antibody says. Previous labeling included a theoretical risk statement regarding anaphylaxis. Labeling now includes data for patient exposure beyond five doses in a single RSV season, stating "adverse events after a sixth or greater dose of Synagis are similar in character and frequency to those after the initial five doses." MedImmune sent a "Dear Healthcare Professional" letter regarding the changes Nov. 26...
You may also be interested in...
AAM Welcomes Proposal To Update Medicare Part D
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: